Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The proteasome regulates cellular processes as diverse as cell cycle progression and NF-κB activation. In this study, we show that the potent antitumor natural product epoxomicin specifically targets the proteasome. Utilizing biotinylated-epoxomicin as a molecular probe, we demonstrate that epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome. Enzymatic analyses with purified bovine erythrocyte proteasome reveal that epoxomicin potently inhibits primarily the chymotrypsin-like activity. The trypsin-like and peptidyl-glutamyl peptide hydrolyzing catalytic activities also are inhibited at 100- and 1,000-fold slower rates, respectively. In contrast to peptide aldehyde proteasome inhibitors, epoxomicin does not inhibit nonproteasomal proteases such trypsin, chymotrypsin, papain, calpain, and cathepsin B at concentrations of up to 50 μM. In addition, epoxomicin is a more potent inhibitor of the chymotrypsin-like activity than lactacystin and the peptide vinyl sulfone NLVS. Epoxomicin also effectively inhibits NF-κB activation in vitro and potently blocks in vivo inflammation in the murine ear edema assay. These results thus define epoxomicin as a novel proteasome inhibitor that likely will prove useful in exploring the role of the proteasome in various in vivo and in vitro systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB AND REL PROTEINS: Evolutionarily Conserved Mediators of Immune Responses
Ghosh, S., May, M. J., & Kopp, E. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.225 · Cited by 5,182
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES
Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,487
Structure of 20S proteasome from yeast at 2.4Å resolution
Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,257
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
The ubiquitin-proteasome pathway: on protein death and cell life
Ciechanover, A. (1998) · The EMBO Journal · doi:10.1093/emboj/17.24.7151 · Cited by 1,426
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the δ domain
Treier, M., Staszewski, L. M., & Bohmann, D. (1994) · Cell · doi:10.1016/s0092-8674(94)90502-9 · Cited by 923
Traenckner, E. B., Wilk, S., & Baeuerle, P. A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06878.x · Cited by 710
Cited by
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Self-citationCatalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citationImpact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
Proteasome inhibitors: from research tools to drug candidates
Kisselev, A. F., & Goldberg, A. L. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(01)00056-4 · Cited by 1,184
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Role of Rpn11 Metalloprotease in Deubiquitination and Degradation by the 26 S Proteasome
Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J. R., Koonin, E. V., & Deshaies, R. J. (2002) · Science · doi:10.1126/science.1075898 · Cited by 1,000
The proteasome: overview of structure and functions
TANAKA, K. (2009) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.85.12 · Cited by 862
Prohibitin 2 Is an Inner Mitochondrial Membrane Mitophagy Receptor
Wei, Y., Chiang, W.-C., Sumpter, R., Mishra, P., & Levine, B. (2017) · Cell · doi:10.1016/j.cell.2016.11.042 · Cited by 842
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
The ubiquitin-proteasome system
Nandi, D., Tahiliani, P., Kumar, A., & Chandu, D. (2006) · Journal of Biosciences · doi:10.1007/bf02705243 · Cited by 758
Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3–independent β-catenin degradation
Topol, L., Jiang, X., Choi, H., Garrett-Beal, L., Carolan, P. J., & Yang, Y. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200303158 · Cited by 724
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Self-citationNatural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
Nijhawan, D., Fang, M., Traer, E., Zhong, Q., Gao, W., Du, F., & Wang, X. (2003) · Genes & Development · doi:10.1101/gad.1093903 · Cited by 591
The proteasome: structure, function, and role in the cell
ADAMS, J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00081-1 · Cited by 585
Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools
Greenbaum, D., Medzihradszky, K. F., Burlingame, A., & Bogyo, M. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00014-4 · Cited by 581
Dantuma, N. P., Lindsten, K., Glas, R., Jellne, M., & Masucci, M. G. (2000) · Nature Biotechnology · doi:10.1038/75406 · Cited by 553
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517
Self-citationBorodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H. S., Wilkinson, K. D., & Ploegh, H. L. (2001) · The EMBO Journal · doi:10.1093/emboj/20.18.5187 · Cited by 504
Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle
Dryden, S. C., Nahhas, F. A., Nowak, J. E., Goustin, A.-S., & Tainsky, M. A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.9.3173-3185.2003 · Cited by 498
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00442 · Cited by 488
Self-citationChemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 487
Self-citationTargeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Self-citationThe ubiquitin‐proteasome pathway and proteasome inhibitors
Myung, J., Kim, K. B., & Crews, C. M. (2001) · Medicinal Research Reviews · doi:10.1002/med.1009 · Cited by 446
Self-citationDrugging the undruggables: exploring the ubiquitin system for drug development
Huang, X., & Dixit, V. M. (2016) · Cell Research · doi:10.1038/cr.2016.31 · Cited by 427
The Transcription Factor NF-κB and the Regulation of Vascular Cell Function
de Martin, R., Hoeth, M., Hofer-Warbinek, R., & Schmid, J. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.11.e83 · Cited by 408
20S Proteasome and Its Inhibitors: Crystallographic Knowledge for Drug Development
Borissenko, L., & Groll, M. (2007) · Chemical Reviews · doi:10.1021/cr0502504 · Cited by 407
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Self-citationJung, T., Catalgol, B., & Grune, T. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.04.001 · Cited by 389
Salami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Self-citationBargagna-Mohan, P., Hamza, A., Kim, Y.-E., Khuan (Abby) Ho, Y., Mor-Vaknin, N., Wendschlag, N., Liu, J., Evans, R. M., Markovitz, D. M., Zhan, C.-G., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.04.010 · Cited by 348
Self-citationMonitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic Peptide Substrates
Kisselev, A. F., & Goldberg, A. L. (2005) · Methods in Enzymology · doi:10.1016/s0076-6879(05)98030-0 · Cited by 346
Protein degradation and the generation of MHC class I-presented peptides
Rock, K. L., York, I. A., Saric, T., & Goldberg, A. L. (2002) · Advances in Immunology · doi:10.1016/s0065-2776(02)80012-8 · Cited by 339
Schubert, U., Ott, D. E., Chertova, E. N., Welker, R., Tessmer, U., Princiotta, M. F., Bennink, J. R., Kräusslich, H.-G., & Yewdell, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13057 · Cited by 339
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy
Deshaies, R. J. (2014) · BMC Biology · doi:10.1186/s12915-014-0094-0 · Cited by 337
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro
Garrett, I. R., Chen, D., Gutierrez, G., Zhao, M., Escobedo, A., Rossini, G., Harris, S. E., Gallwitz, W., Kim, K. B., Hu, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16198 · Cited by 328
Self-citationSinner, D., Kordich, J. J., Spence, J. R., Opoka, R., Rankin, S., Lin, S.-C. J., Jonatan, D., Zorn, A. M., & Wells, J. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02179-06 · Cited by 321
Current Advances in Detection and Treatment of Babesiosis
Mosqueda, J., Olvera-Ramirez, A., Aguilar-Tipacamu, G., & Canto, G. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799828355 · Cited by 319
Recognition of Bacteria in the Cytosol of Mammalian Cells by the Ubiquitin System
Perrin, A. J., Jiang, X., Birmingham, C. L., So, N. S. Y., & Brumell, J. H. (2004) · Current Biology · doi:10.1016/j.cub.2004.04.033 · Cited by 311
Fricker, L. D. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023603 · Cited by 309
Catalytic Activities of the 20 S Proteasome, a Multicatalytic Proteinase Complex
Orlowski, M., & Wilk, S. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2000.2036 · Cited by 308
A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism
Groll, M., Schellenberg, B., Bachmann, A. S., Archer, C. R., Huber, R., Powell, T. K., Lindow, S., Kaiser, M., & Dudler, R. (2008) · Nature · doi:10.1038/nature06782 · Cited by 308
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Self-citationImpairment of proteasome structure and function in aging
Carrard, G., Bulteau, A.-L., Petropoulos, I., & Friguet, B. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00085-7 · Cited by 301
Large-scale identification of ubiquitination sites by mass spectrometry
Udeshi, N. D., Mertins, P., Svinkina, T., & Carr, S. A. (2013) · Nature Protocols · doi:10.1038/nprot.2013.120 · Cited by 296
Ma, J., & Lindquist, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011578098 · Cited by 294
Ubiquitin is part of the retrovirus budding machinery
Patnaik, A., Chau, V., & Wills, J. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13069 · Cited by 292
Conversion of PrP to a Self-Perpetuating PrP Sc -like Conformation in the Cytosol
Ma, J., & Lindquist, S. (2002) · Science · doi:10.1126/science.1073619 · Cited by 287
Alavi, M. V., Bette, S., Schimpf, S., Schuettauf, F., Schraermeyer, U., Wehrl, H. F., Ruttiger, L., Beck, S. C., Tonagel, F., Pichler, B. J., et al. (2006) · Brain · doi:10.1093/brain/awm005 · Cited by 282
Electrophilic natural products and their biological targets
Gersch, M., Kreuzer, J., & Sieber, S. A. (2012) · Natural Product Reports · doi:10.1039/c2np20012k · Cited by 282
Xu, J., Kurup, P., Zhang, Y., Goebel-Goody, S. M., Wu, P. H., Hawasli, A. H., Baum, M. L., Bibb, J. A., & Lombroso, P. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2212-09.2009 · Cited by 280
The structural modification of natural products for novel drug discovery
Yao, H., Liu, J., Xu, S., Zhu, Z., & Xu, J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1272757 · Cited by 275
Zhou, H.-J., Aujay, M. A., Bennett, M. K., Dajee, M., Demo, S. D., Fang, Y., Ho, M. N., Jiang, J., Kirk, C. J., Laidig, G. J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801329v · Cited by 272
Butyrate Suppression of Colonocyte NF-κB Activation and Cellular Proteasome Activity
Yin, L., Laevsky, G., & Giardina, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105170200 · Cited by 266
MacLean, A. M., Orlovskis, Z., Kowitwanich, K., Zdziarska, A. M., Angenent, G. C., Immink, R. G. H., & Hogenhout, S. A. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001835 · Cited by 266
New Approaches and Therapeutics Targeting Apoptosis in Disease
Fischer, U., & Schulze-Osthoff, K. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.6 · Cited by 257
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. (2000) · Worldwide Protein Data Bank · doi:10.2210/pdb1g65/pdb · Cited by 253
Self-citationTHE PROTEASOME AND PROTEASOME INHIBITORS IN CANCER THERAPY
Voorhees, P. M., & Orlowski, R. Z. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141300 · Cited by 247
Activity-based probes as a tool for functional proteomic analysis of proteases
Fonović, M., & Bogyo, M. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.5.721 · Cited by 231
Kabuta, T., Suzuki, Y., & Wada, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603337200 · Cited by 219
Sha, Z., & Goldberg, A. L. (2014) · Current Biology · doi:10.1016/j.cub.2014.06.004 · Cited by 215
Natural Products and Their Biological Targets: Proteomic and Metabolomic Labeling Strategies
Böttcher, T., Pitscheider, M., & Sieber, S. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200905352 · Cited by 212
Dietrich, J.-B., Mangeol, A., Revel, M.-O., Burgun, C., Aunis, D., & Zwiller, J. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.01.018 · Cited by 168
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Self-citationRamachandran, K. V., & Margolis, S. S. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3389 · Cited by 151
FUERTES, G., DE LLANO, J. J. M., VILLARROYA, A., RIVETT, A. J., & KNECHT, E. (2003) · Biochemical Journal · doi:10.1042/bj20030282 · Cited by 149
Nogalska, A., Terracciano, C., D’Agostino, C., King Engel, W., & Askanas, V. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0564-6 · Cited by 134
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
Bery, N., Miller, A., & Rabbitts, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17022-w · Cited by 132
Rockwell, P., Yuan, H., Magnusson, R., & Figueiredo-Pereira, M. E. (2000) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1646 · Cited by 130
Wang, J.-H., Janas, A. M., Olson, W. J., & Wu, L. (2007) · Journal of Virology · doi:10.1128/jvi.00878-07 · Cited by 125
Regulation of apoptosis by the ubiquitin and proteasome pathway
Wójcik, C. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00309.x · Cited by 118
Nogalska, A., D'Agostino, C., Terracciano, C., Engel, W. K., & Askanas, V. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100050 · Cited by 114
Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., de Yébenes, J. G., & Mena, M. A. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.01.008 · Cited by 114
“Epoxomicin and other UPS inhibitors induce the accumulation of p53 and ubiquitinated proteins (Meng et al., 1999; Pan et al., 2008).”
BackgroundFratta, P., Engel, W. K., McFerrin, J., Davies, K. J. A., Lin, S. W., & Askanas, V. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62994-x · Cited by 111
Aging and regulated protein degradation: who has the UPPer hand?
Vernace, V. A., Schmidt‐Glenewinkel, T., & Figueiredo‐Pereira, M. E. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00329.x · Cited by 110
Pozhidaeva, A., Valles, G., Wang, F., Wu, J., Sterner, D. E., Nguyen, P., Weinstock, J., Kumar, K. G. S., Kanyo, J., Wright, D., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.004 · Cited by 107
Profiling proteasome activity in tissue with fluorescent probes
Berkers, C. R., van Leeuwen, F. W. B., Groothuis, T. A., Peperzak, V., van Tilburg, E. W., Borst, J., Neefjes, J. J., & Ovaa, H. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700256 · Cited by 102
Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway
Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1209974 · Cited by 95
“Unlike several widely used PIs, Epoxo is highly specific for the proteasome without affecting the activity of other non-proteasomal proteases including calpain, trypsin and cathepsin B (Meng et al., 1999).”
BackgroundInfluentialClinical development of novel proteasome inhibitors for cancer treatment
Yang, H., Zonder, J. A., & Dou, Q. P. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903002074 · Cited by 85
A novel mechanism for the regulation of amyloid precursor protein metabolism
Chen, Q., Kimura, H., & Schubert, D. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200110151 · Cited by 63
Wojcikiewicz, R. J. H., Xu, Q., Webster, J. M., Alzayady, K., & Gao, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206607200 · Cited by 63
Døskeland, A. P., & Flatmark, T. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.02808.x · Cited by 53
BAMBI Is Expressed in Endothelial Cells and Is Regulated by Lysosomal/Autolysosomal Degradation
Xavier, S., Gilbert, V., Rastaldi, M. P., Krick, S., Kollins, D., Reddy, A., Bottinger, E., Cohen, C. D., & Schlondorff, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012995 · Cited by 46
Ionizing radiation induces ATM-independent degradation of p21Cip1 in transformed cells
Stuart, S. A., & Wang, J. Y. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808810200 · Cited by 28
Liu, T., Huang, Y., Likhotvorik, R. I., Keshvara, L., & Hoyt, D. G. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00366.2007 · Cited by 25
Nakashima, A., Ohnuma, S., Kodani, Y., Kaneko, Y. S., Nagasaki, H., Nagatsu, T., & Ota, A. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.022 · Cited by 22
Cellular assembly and functional resilience of the mammalian RNA exosome
Navalayeu, T., Beer, N., Bebjaková, M., Kalis, R. W., Hohmann, U., Stejskal, K., Krššáková, G., Fasching, N., Herzog, V. A., Popitsch, N., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00824-x
Metadata
- Authors
- Meng, L., Mohan, R., Kwok, B. H. B., Elofsson, M., Sin, N., & Crews, C. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-08-31
- Volume
- 96
- Issue
- 18
- Pages
- 10403-10408
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2159831275
- Cited by
- 920
- References
- 39
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.